Investor Presentaiton

Income statement DKKm Revenue Gross profit SG&A costs R&D costs Q3 2021/22 Q3 2022/23 Change 9M 2021/22 9M 2022/23 Change 5,849 6,108 4% 16,520 18,274 11% 4,048 4,023 -1% 11,359 12,196 7% -2,083 -2,128 2% -5,654 -6,449 14% -222 -216 -3% -649 -641 -1% Other operating income/expenses 18 7 -61% 40 25 -38% Operating profit (EBIT) before special items 1,761 1,686 -4% 5,096 5,131 1% Special items -20 28 nm -435 -5 nm Operating profit (EBIT) 1,741 1,714 -2% 4,661 5,126 10% Net financial items -70 -104 49% -146 -628 330% Ταχ Net profit Key ratios -382 -338 -12% -1,039 -944 -9% 1,289 1,272 -1% 3,476 3,554 2% Gross margin 69% 66% 69% 67% EBIT margin before special items 30% 28% 31% 28% EBIT margin 30% 28% 28% 28% Earnings per share (EPS) before special items, diluted 6.13 5.88 -4% 17.90 16.74 -6% 99 99 Coloplast

View entire presentation